
MedinCell Announces Share Capital and Voting Rights Update
Paris, France – July 3, 2025 – MedinCell, a biopharmaceutical company dedicated to developing long-acting injectable medicines, has today released important information regarding its share capital and the total number of voting rights. This disclosure, published by Business Wire French Language News, provides key details for investors and stakeholders.
According to the announcement, MedinCell’s total number of shares making up its share capital currently stands at [Insert number of shares here, if available in the article]. Concurrently, the company has confirmed that the total number of voting rights exercisable amounts to [Insert number of voting rights here, if available in the article].
These figures are fundamental for understanding the current structure of MedinCell’s ownership and the overall voting power within the company. Such information is crucial for shareholders, particularly when it comes to participating in general meetings and influencing corporate decisions.
MedinCell’s commitment to transparent communication is underscored by this regular update. By providing clear and accessible information on its share capital and voting rights, the company aims to foster trust and facilitate informed decision-making among its investor base.
The company continues its work on developing innovative long-acting injectable formulations, seeking to improve patient adherence and treatment outcomes across various therapeutic areas. This latest disclosure serves as a routine update on the company’s financial and governance structure, supporting its ongoing development and growth.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘MedinCell : Information relative au nombre d’actions composant le capital social et au nombre total des droits de vote’ at 2025-07-03 18:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.